NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/25/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,033.45 mln
Float40.15 mln
Earnings Date11/05/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-5.52
Highly reliable
1-Year Forecast
44.15
Transformational upside
Relative Strength
70
/ 100
Outperforming
Debt / Equity
0.00
Debt-free
ROE
-63.01
Deeply negative
Business Description
Founded in 2011 and based in Rockville, Maryland, Avalo Therapeutics is a U.S. biotech company working to bring new treatments to patients whose immune systems cause harmful inflammation. The company's most advanced drug candidate, AVTX-009, is currently being tested in a mid-stage clinical trial targeting a protein linked to inflammatory conditions. Previously operating under the name Cerecor Inc., the company rebranded as Avalo Therapeutics in August 2021.
